Xiangyu Pharmaceutical Co., Ltd. is a famous trademark in Shandong Province, a well-known brand of maternal and child blood supplementation, a high-tech enterprise, and a large-scale modern private pharmaceutical enterprise
Siangyu Pharmaceutical Co., Ltd. is a listed company controlled by Siangyu Group. (National Small and Medium-sized Enterprises Share Transfer System, stock code 832276) is the vice president unit of the Pharmaceutical Chamber of Commerce of the All-China Federation of Industry and Commerce. It has a wholly-owned subsidiary (Shandong Renhetang Pharmaceutical Co., Ltd.) and a holding company (two subsidiaries of Shandong Nowells Pharmaceutical Technology Co., Ltd.). It has two production bases: Traditional Chinese Medicine Health Park and Renhetang Medicine Park. It produces 11 types of preparations such as gynecology, pediatrics, psychiatry, tonics, cardiovascular and cerebrovascular drugs, as well as more than 300 specifications of 138 varieties of APIs. There are more than 200 drugs with independent intellectual property rights, independent pricing rights, national protected varieties of traditional Chinese medicine, and more than 200 drugs that have entered the national medical insurance, basic drugs, and new agricultural cooperative medicine catalog.
Xiangyu Pharmaceutical adheres to the enterprise development strategy of "building a first-line pharmaceutical enterprise for maternal and child medicine in China", and has cooperated with more than 3,000 distributors and more than 100,000 medical pharmacy terminals, with a sales network all over the country, and some products are exported to Europe and the United States, providing professional and high-quality products and services for more and more families!
"Maternal and child medicine, Xiangyu made". China's well-known trademark "Xiangyu Hongyi" series of maternal and child medicines includes more than 20 products and more than 60 specifications. The national patented variety, medicine and food homologous product "Compound Hongyi Blood Replenishing Oral Liquid" was selected by the Ministry of Science and Technology as the "National Torch Program Project Traditional Chinese Medicine Variety", and has now grown into the first brand of maternal and children's plant blood supplementation, ranking first in sales volume for three consecutive years in the market segment, in 2015, "Compound Hongyi Blood Replenishing Oral Liquid" was rated as "China Pharmaceutical Enterprise Growth Product Brand" by CFDA Southern. The national traditional Chinese medicine protected variety "Compound Yimu Capsule" occupies the forefront of the sales of menstrual regulating varieties in China (ranking sixth). The special drug for premenstrual syndrome "premenstrual pills" is an innovative variety of classic prescriptions to fill the gap in the domestic and foreign markets; The national exclusive variety, national patented variety, and the three types of new drugs of national traditional Chinese medicine, "Puling Basin Yankang Granules", enjoy the reputation of traditional Chinese medicine antibiotics. "Xiangmahan Asthma Patch" is the only internal and external treatment preparation for the treatment of pediatric asthma by sticking back acupuncture points. The chemical drug difenidol hydrochloride has obtained DMF registration in the United States, and the raw materials of mianserin hydrochloride and fleroxacin lactate are the exclusive domestic products to replace imports, and the products are sold to Japan, Mexico, the United States and other countries and regions.
Siangyu Pharmaceutical Co., Ltd. is designed in strict accordance with the requirements of the new version of GMP, implements a high-standard GMP production system and quality system, and implements internal control standards that are higher than the national standard. In recent years, it has invested 350 million yuan to upgrade the production system and ecological treatment system. The new multi-functional extraction workshop and comprehensive solid preparation workshop have been built, and the automatic control system and international advanced drug testing equipment have been introduced to ensure the stability and excellence of product quality.
Xiangyu Pharmaceutical Co., Ltd. has technical qualifications such as high-tech enterprises, China patent star enterprises, traditional Chinese medicine modern science and technology demonstration enterprises, and one enterprise and one technological innovation enterprise in Shandong Province, and has successively established scientific research and innovation platforms such as Shi Xuemin Academician Workstation, Nowells Technology Co., Ltd., Postdoctoral Research Workstation, and Engineering Research Center for New Gynecological Drug Preparations. More than 10 medical research institutions such as Beijing University of Chinese Medicine have cooperated to provide lasting power for the sustainable development of enterprises. The company has applied for 52 product patents, 29 of which have been approved, and drafted national quality standards for many drugs such as Compound Hongyi Blood Replenishing Oral Liquid, Compound Yimu Capsule, and Puling Basin Yankang Granules. It has completed 23 major national and provincial projects, 19 technical breakthroughs, and more than 30 quality standard improvement studies. At present, the company has more than 30 new products under development, and the original varieties such as adamante dispersible tablets, axilimus capsules, and bloodflow oral liquid varieties have been approved for marketing.
Siangyu Pharmaceutical has been awarded the "Top 10 Most Growing Enterprises in China's Pharmaceutical Power List", "Top 50 Most Influential Members in China's Pharmaceutical Industry", and "2014 Most Valuable Investment Enterprise in the Pharmaceutical Industry". In the next five years, Siangyu Pharmaceutical will continue to focus on the core goal of building "China's first-line pharmaceutical enterprise for maternal and child medicine", adhering to the development concept of "quality first, efficiency first, brand leading, and scientific and technological innovation", implement the six strategies of resources, technology, brand, talent, internationalization and standards, continuously consolidate and enhance the core competitiveness of the enterprise, and achieve the leapfrog development goal of entering the top 100 pharmaceutical industries in China!
Integrity Xiangyu healthy peers
